Biotek-snakken — August 2022
-
2cureX - interim report for H1 2022 https://www.proinvestor.com/boards/105587
-
InvestorBAVA: ExpreS2ion er blevet lidt mere specifikke for breast cancer vaccinen i halvårsrapporten. Nu siger de filing af clinical study H2 2023 og start 2024. Håber, at de lykkes med vaccinen. In vivo resultaterne i mus ser i hvert fald særdeles lovende ud.
-
Zymeworks targeting cancer with next-gen multifunctional biotherapeutics - BioTuesdays
Zymeworks (NYSE:ZYME) is leading a paradigm shift developing next-generation multifunctional antibodies and antibody drug conjugates, with an initial focus on HER2-targeted therapies to treat cancer.
BioTuesdays (biotuesdays.com)
-
“We have legacy partnerships and future milestones coming to us, which we could monetize with someone else for upfront liquidity and pass those future payments on to a financing partner,” he adds. “We hope to announce something about that later this year.”
-
Mød Genmab A/S Vice President, Head of Investor Relations Andrew Carlsen i en online Q&A session om selskabet og Q2 rapporten mandag d. 29. August kl. 15.00.
Moderator: Helge Larsen.Spørgsmål skal stilles på forhånd på engelsk i Q&A chatten. Deadline mandag kl. 12.
Tilmelding på link.
-
Biotech Stocks Facing FDA Decision In September https://www.proinvestor.com/investornyt/871985/biotech-stocks-facing-fda-decision-in-september
-
Trancript fra Q&A med CEO Adam Stensberg/Zealand Pharma Q2 afholdt i går kl. 15. https://www.proinvestor.com/ir/q-and-a/dk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind